Syntara Alternatives & Competitors
11 companies similar to Syntara — Syntara (ASX:SNT) is an ASX-listed clinical stage drug developer for diseases li...
Companies similar to Syntara
Nordic Bioscience
Improving preclinical and clinical trial success rates with world-leading biomarkers & spe...
Salmedix
Pioneering advanced treatments for blood cancers, delivering innovative Phase II clinical...
Third Harmonic Bio
Advancing the next wave of medicine for inflammatory diseases
Chemomab Therapeutics
Developing innovative therapeutics for diseases at confluence of fibrosis and inflammation...
Rival Readout
Competing with Syntara? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
Galmed Pharmaceuticals Ltd.
A clinical-stage drug development biopharmaceutical company for liver, metabolic & inflamm...
GEn1E Lifesciences Inc.
Clinical-stage, Phase 2 company accelerating novel Precision Therapies for I&I and Rare Di...
Redx Pharma
Biotech company focusing on the discovery and development of novel targeted medicines to t...
Relmada Therapeutics, Inc
Relmada (Nasdaq: $RLMD) is a clinical-stage company developing novel therapies for the tre...
BeBetter Med
Clinical-stage drug discovery and development of advanced novel medicines for cancer and o...
Cleave Therapeutics, Inc.
VCP/p97 Inhibitors for Oncology and Neurodegenerative Diseases
Kinarus Therapeutics
Kinarus Therapeutics is a clinical-stage company developing therapies for viral, respirato...
About Syntara
Syntara (ASX:SNT) is a clinical stage drug developer focusing on diseases associated with fibrosis and inflammation. The company, founded in 1998, specializes in targeting extracellular matrix dysfunction using its expertise in amine oxidase chemistry. Its lead candidate SNT-5505 has received FDA Orphan Drug Designatio...
Clinical Stage Drug Development, Extracellular Matrix Dysfunction, Amine Oxidase Chemistry, Drug Candidates, Fibrotic Diseases, Inflammatory Diseases, Blood Cancers, Respiratory Products, Royalties, Neuroinflammation, Chronic Fibrosis, Haematological Malignancies, Myelofibrosis, Myelodysplastic Syndrome, Scar Management
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around Syntara: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at Syntara on 6 Dec 2024. The 11 companies listed here were last checked between 12 Sep 2024 and 9 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.